CTOs on the Move


 
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.
  • Number of Employees: 25-100
  • Annual Revenue: $250-500 Million
  • www.olema.com
  • 665 3rd Street Suite 250
    San Francisco, CA USA 94107
  • Phone: n/a

Executives

Name Title Contact Details

Similar Companies

MK Education

MK Education is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affinium Pharmaceuticals

Affinium Pharmaceuticals , Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.

National Spine & Pain Centers

National Spine & Pain Centers is the nations leading pain practice offering non-surgical treatments for people with pain conditions from head to toe.

HBP

Hudson Botanical Processing is a full-service cannabis manufacturing company serving the operational needs of the cannabis industry. They work with industry-leading cannabis brands to produce and distribute the highest quality products in Massachusetts.